| Title | Pharmacotherapy for adult ADHD. | | Author(s) | Adler LA | | Institution | Department of Psychiatry and Child and Adolescent Psychiatry, New York University School of Medicine and NYU Langone Medical Center, and Psychiatry Service, VA Harbor Healthcare System, NY, USA. | | Source | J Clin Psychiatry 2009 May; 70(5):e12. | | MeSH | Adrenergic Uptake Inhibitors
Adult
Amphetamines
Attention Deficit Disorder with Hyperactivity
Central Nervous System Stimulants
Cognitive Therapy
Combined Modality Therapy
Comorbidity
Humans
Substance-Related Disorders
| | Abstract | The U.S. Food and Drug Administration has approved 3 medications, atomoxetine and the extended-release formulations of amphetamine salts and dexmethylphenidate, for the treatment of adult attention-deficit hyperactivity disorder (ADHD). Different formulations of the same drugs, as well as other agents and cognitive-behavioral therapy, have been tested to determine efficacy in ADHD alone and in ADHD with comorbid substance use disorders, mood disorders, and anxiety disorders. A deficit in research exists in regard to these comorbidities in adults with ADHD. | | Language | eng | | Pub Type(s) | Journal Article
| | PubMed ID | 19552859 |
|
